julien mazieres
julien mazieres
CHU TOULOUSE, INSERM UMR1037, Université Paul Sabatier
Adresse e-mail validée de
Citée par
Citée par
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre …
R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ...
The lancet oncology 13 (3), 239-246, 2012
Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer
L Paz-Ares, A Luft, D Vicente, A Tafreshi, M Gümüş, J Mazières, B Hermes, ...
New England journal of medicine 379 (21), 2040-2051, 2018
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
L Fehrenbacher, A Spira, M Ballinger, M Kowanetz, J Vansteenkiste, ...
The Lancet 387 (10030), 1837-1846, 2016
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase …
NA Rizvi, J Mazières, D Planchard, TE Stinchcombe, GK Dy, SJ Antonia, ...
The lancet oncology 16 (3), 257-265, 2015
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
G Zalcman, J Mazieres, J Margery, L Greillier, C Audigier-Valette, ...
The Lancet 387 (10026), 1405-1414, 2016
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
F Barlesi, J Mazieres, JP Merlio, D Debieuvre, J Mosser, H Lena, ...
The Lancet 387 (10026), 1415-1426, 2016
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
D Planchard, B Besse, HJM Groen, PJ Souquet, E Quoix, CS Baik, ...
The Lancet Oncology 17 (7), 984-993, 2016
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J Mazieres, A Drilon, A Lusque, L Mhanna, AB Cortot, L Mezquita, ...
Annals of Oncology 30 (8), 1321-1328, 2019
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
D Planchard, EF Smit, HJM Groen, J Mazieres, B Besse, Å Helland, ...
The Lancet Oncology 18 (10), 1307-1316, 2017
Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
J Mazieres, S Peters, B Lepage, AB Cortot, F Barlesi, M Beau-Faller, ...
Journal of clinical oncology 31 (16), 1997-2003, 2013
Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy
R Ferrara, L Mezquita, M Texier, J Lahmar, C Audigier-Valette, ...
JAMA oncology 4 (11), 1543-1552, 2018
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ...
The Lancet Oncology 21 (7), 914-922, 2020
Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer
L Mezquita, E Auclin, R Ferrara, M Charrier, J Remon, D Planchard, ...
JAMA oncology 4 (3), 351-357, 2018
First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
AT Shaw, TM Bauer, F de Marinis, E Felip, Y Goto, G Liu, J Mazieres, ...
New England Journal of Medicine 383 (21), 2018-2029, 2020
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study
MC Garassino, BC Cho, JH Kim, J Mazières, J Vansteenkiste, H Lena, ...
The Lancet Oncology 19 (4), 521-536, 2018
Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations
PK Paik, E Felip, R Veillon, H Sakai, AB Cortot, MC Garassino, J Mazieres, ...
New England Journal of Medicine 383 (10), 931-943, 2020
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
D Planchard, TM Kim, J Mazieres, E Quoix, G Riely, F Barlesi, PJ Souquet, ...
The Lancet Oncology 17 (5), 642-650, 2016
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.
J Mazières, G Zalcman, L Crinò, P Biondani, F Barlesi, T Filleron, ...
Journal of clinical oncology: official journal of the American Society of …, 2015
A randomized, placebo-controlled trial of pembrolizumab plus chemotherapy in patients with metastatic squamous NSCLC: protocol-specified final analysis of KEYNOTE-407
L Paz-Ares, D Vicente, A Tafreshi, A Robinson, HS Parra, J Mazières, ...
Journal of Thoracic Oncology 15 (10), 1657-1669, 2020
Wnt signaling in lung cancer
J Mazieres, B He, L You, Z Xu, DM Jablons
Cancer letters 222 (1), 1-10, 2005
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20